ID: ALA447809

Max Phase: Preclinical

Molecular Formula: C13H20N2O

Molecular Weight: 220.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCN1CCN(c2cccc(O)c2)CC1

Standard InChI:  InChI=1S/C13H20N2O/c1-2-6-14-7-9-15(10-8-14)12-4-3-5-13(16)11-12/h3-5,11,16H,2,6-10H2,1H3

Standard InChI Key:  AWROKCIGUWAVRF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 220.32

Molecular Weight (Monoisotopic): 220.1576

AlogP: 1.92

#Rotatable Bonds: 3

Polar Surface Area: 26.71

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.79

CX Basic pKa: 8.38

CX LogP: 2.34

CX LogD: 1.46

Aromatic Rings: 1

Heavy Atoms: 16

QED Weighted: 0.84

Np Likeness Score: -1.15

References

1. Lacivita E, Leopoldo M, De Giorgio P, Berardi F, Perrone R..  (2009)  Determination of 1-aryl-4-propylpiperazine pKa values: the substituent on aryl modulates basicity.,  17  (3): [PMID:19121584] [10.1016/j.bmc.2008.12.015]

2. Pettersson F, Pontén H, Waters N, Waters S, Sonesson C..  (2010)  Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).,  53  (6): [PMID:20155917] [10.1021/jm901689v]

3. Pettersson F, Svensson P, Waters S, Waters N, Sonesson C..  (2013)  Synthesis, pharmacological evaluation and QSAR modeling of mono-substituted 4-phenylpiperidines and 4-phenylpiperazines.,  62  [PMID:23353756] [10.1016/j.ejmech.2012.12.031]

Source

Source(1):

• Scientific Literature